Cargando…

Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study

PURPOSE: To investigate the impact of metabolic syndrome (MetS) on pathologic complete response (pCR) and clinical outcomes in breast cancer (BC) patients who received neoadjuvant chemotherapy (NAC). METHODS: We analyzed 221 female BC patients at Harbin Medical University Cancer Hospital who receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Zhaoyue, Zhang, Yue, Li, Yue, Jiang, Cong, Wu, Yang, Shang, Lingmin, Huang, Yuanxi, Cheng, Shaoqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845900/ https://www.ncbi.nlm.nih.gov/pubmed/36686748 http://dx.doi.org/10.3389/fonc.2022.1080054

Ejemplares similares

Predictive value of controlling nutritional status score in postoperative recurrence and metastasis of breast cancer patients with HER2-low expression
por: Li, Yue, et al.
Publicado: (2023)

Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Lu, Ying, et al.
Publicado: (2022)

Mammographic density in relation to breast cancer recurrence and survival in women receiving neoadjuvant chemotherapy
por: Zdanowski, Anna, et al.
Publicado: (2023)

Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy
por: Song, Yu-Chun, et al.
Publicado: (2023)

An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine
por: Wang, Mozhi, et al.
Publicado: (2021)

Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis
por: Zhou, Qiong, et al.
Publicado: (2021)

Breast microbiome associations with breast tumor characteristics and neoadjuvant chemotherapy: A case-control study
por: Li, Xuejun, et al.
Publicado: (2022)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy
por: Gao, Siming, et al.
Publicado: (2023)

Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Jiang, Cong, et al.
Publicado: (2020)

Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer
por: Meng, Xiangyu, et al.
Publicado: (2022)

Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy
por: Zheng, Chen, et al.
Publicado: (2023)

Long-Term Survival in Nonsurgical Esophageal Cancer Patients Who Received Consolidation Chemotherapy Compared With Patients Who Received Concurrent Chemoradiotherapy Alone: A Systematic Review and Meta-Analysis
por: Xia, Xiaojie, et al.
Publicado: (2021)

Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022)

Body composition change during neoadjuvant chemotherapy for breast cancer
por: Jang, Min Kyeong, et al.
Publicado: (2022)

Contrast-enhanced ultrasonography for early prediction of response of neoadjuvant chemotherapy in breast cancer
por: Guo, Jiabao, et al.
Publicado: (2022)

Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy
por: Jiang, Cong, et al.
Publicado: (2022)

Questionnaire study of application about sentinel lymph node biopsy surgery in locally advanced breast cancer patients who received neoadjuvant chemotherapy
por: Lee, Eun-Gyeong, et al.
Publicado: (2023)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
por: Cao, Maria D, et al.
Publicado: (2012)

Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes
por: Adham, Sirin A., et al.
Publicado: (2022)

Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress
por: Chen, Yushi, et al.
Publicado: (2023)

A Novel Model Incorporating Tumor Stiffness, Blood Flow Characteristics, and Ki-67 Expression to Predict Responses After Neoadjuvant Chemotherapy in Breast Cancer
por: Zhang, Jing, et al.
Publicado: (2020)

Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy
por: Zhao, Yue, et al.
Publicado: (2019)

A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Jiang, Cong, et al.
Publicado: (2022)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

Influence of Adjuvant Radiotherapy Timing on Survival Outcomes in High-Risk Patients Receiving Neoadjuvant Treatments
por: Cao, Lu, et al.
Publicado: (2022)

A Decision-Making Supporting Prediction Method for Breast Cancer Neoadjuvant Chemotherapy
por: Song, Dong, et al.
Publicado: (2021)

Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review
por: Zhao, Yueqiu, et al.
Publicado: (2022)

Impact of Atypical Hyperplasia at Surgical Margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy
por: Su, An, et al.
Publicado: (2023)

An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy
por: Dieli‐Conwright, Christina M., et al.
Publicado: (2016)

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
por: Gong, Yajie, et al.
Publicado: (2020)

Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
por: Dai, Huijuan, et al.
Publicado: (2021)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
por: Wang, Gang, et al.
Publicado: (2023)

Predicting pathological complete response after neoadjuvant chemotherapy: A nomogram combining clinical features and ultrasound semantics in patients with invasive breast cancer
por: Wang, Ke-Nie, et al.
Publicado: (2023)

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
por: Dai, Fuqiang, et al.
Publicado: (2022)

The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis
por: Cheng, Qingqing, et al.
Publicado: (2020)

Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study
por: Sang, Yuting, et al.
Publicado: (2022)

Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS
por: Wang, Qiong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_46qchodvedec3d898f2l7rpnt9